Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development

被引：0
|
作者：
van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh [1 ,2 ]
Van Criekingen, Olga Kholmanskikh [3 ]
Koole, Simone [4 ]
Thomas, David M. [5 ]
Gelderblom, Hans [1 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands
[2] CZ Hlth Insurance, Med Dept, Tilburg, Netherlands
[3] Belgian Fed Agcy Med & Hlth Prod FAMHP, Brussels, Belgium
[4] Zilveren Kruis, Med Advisory Dept, Zeist, Netherlands
[5] Univ New South Wales, Ctr Mol Oncol, Sydney, NSW, Australia
来源：
CANCER CELL | 2024年 / 42卷 / 06期
关键词：
HOMOLOGOUS RECOMBINATION DEFICIENCY;
D O I：
10.1016/j.ccell.2024.05.014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Various tests based on different biomarkers have been developed to identify the best candidates for poly(ADP-ribose) polymerase (PARP)-inhibitor therapy. However, due to the absence of harmonization regarding these complex biomarkers, along with various cutoff points and unknown spatial and temporal variations, it is difficult to define the clinical utility of each test and ensure uniformity in treatment decision-making. Here, we propose measures to align biomarker definitions and minimum analytical performance characteristics for diagnostics to ensure equitable and sustainable access to precision medicine.
引用
收藏
页码：923 / 929
页数：7
相关论文
共 50 条
  • [21] Development and Testing of Icephobic Materials: Lessons Learned from Fraunhofer IFAM
    Rehfeld, Nadine
    Stake, Andrej
    Stenzel, Volkmar
    CONTAMINATION MITIGATING POLYMERIC COATINGS FOR EXTREME ENVIRONMENTS, 2019, 284 : 145 - 166
  • [22] The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology
    Boccardi, Marina
    Gallo, Valentina
    Yasui, Yutaka
    Vineis, Paolo
    Padovani, Alessandro
    Mosimann, Urs
    Giannakopoulos, Panteleimon
    Gold, Gabriel
    Dubois, Bruno
    Jack, Clifford R., Jr.
    Winblad, Bengt
    Frisoni, Giovanni B.
    Albanese, Emiliano
    NEUROBIOLOGY OF AGING, 2017, 52 : 141 - 152
  • [23] Predictive Gene Diagnostics - Biomarker-Based Individualised Drug Therapy
    Dingermann, T.
    Zuendorf, I.
    AKTUELLE NEUROLOGIE, 2011, 38 (10) : 525 - 532
  • [24] Controlling placebo response in drug development: Lessons learned from psychopharmacology
    Potter W.Z.
    Mallinckrodt C.H.
    Detke M.J.
    Pharmaceutical Medicine, 2014, 28 (2) : 53 - 65
  • [25] Clinic-Based Palliative Care: Lessons Learned
    Skold, Anna
    Riendeau, Allison
    Dausner, Jane
    Anderson, Cathy
    Stowers, Ashley
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2016, 51 (02) : 358 - 358
  • [26] Lessons learned from a multidisciplinary renal genetics clinic
    Alkanderi, S.
    Yates, L. M.
    Johnson, S. A.
    Sayer, J. A.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2017, 110 (07) : 453 - 457
  • [27] Biomarker-based adaptive trials for patients With glioblastoma-lessons from I-SPY 2
    Alexander, Brian M.
    Wen, Patrick Y.
    Trippa, Lorenzo
    Reardon, David A.
    Yung, Wai-Kwan Alfred
    Parmigiani, Giovanni
    Berry, Donald A.
    NEURO-ONCOLOGY, 2013, 15 (08) : 972 - 978
  • [28] Lessons learned from usability testing of the documentation
    Barnum, C
    45TH ANNUAL CONFERENCE ON IMAGINATION, INNOVATION AND COMMUNICATION, 1998, : 334 - 334
  • [29] Observations and lessons learned from automated testing
    Berner, S
    Weber, R
    Keller, RK
    ICSE 05: 27th International Conference on Software Engineering, Proceedings, 2005, : 571 - 579
  • [30] Bioethical Dilemmas in Conflict Zones: An Ethicist's Perspective Based on Lessons Learned from Gaza
    Arawi, Thalia
    SEMINARS IN NEPHROLOGY, 2020, 40 (04) : 421 - 428
12345